Drug
Vitamin K Antagonist clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2002 (1)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Bristol-Myers Squibb (1) · Janssen Scientific Affairs, LLC (1) · GlaxoSmithKline (1) · Sanofi (1) · IHF GmbH - Institut für Herzinfarktforschung (1)
Often tested with
Tested in the same studies.
Rivaroxaban (2) · Apixaban (1) · Aspirin (1) · Fondaparinux (1) · Heparin (1) · Idraparinux (1) · Clopidogrel (1) · Dabigatran (1)
Studies
Open first, then newest update. How each study uses Vitamin K Antagonist is read from its arms, and is right about nine times in ten.
Testing it · 6
- D-dimer to Establish Duration of Anticoagulation After Venous ThromboembolismCompletedPhase 4IRCCS Azienda Ospedaliero-Universitaria di BolognaNCT00264277Written as Vitamin K antagonist (Coumarin anticoagulants)
- A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the HeartCompletedPhase 4Bristol-Myers SquibbNCT02415400Written as vitamin K antagonist
- A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary InterventionCompletedPhase 3Janssen Scientific Affairs, LLCNCT01830543Written as vitamin K antagonist (VKA)
- COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome TrialsWithdrawnPhase 4IHF GmbH - Institut für HerzinfarktforschungNCT02723981Written as Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
- Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart RhythmCompletedPhase 2GlaxoSmithKlineNCT00911300Written as Vitamin-K-Antagonist
- Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)CompletedPhase 3SanofiNCT00070655Written as vitamin K antagonist (warfarin or acenocoumarol) tablets
As the comparator · 12 — what is tested is compared with Vitamin K Antagonist
- Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve ReplacementRecruitingPhase 4Joon Bum KimNCT04258488Written as Vitamin K antagonist(warfarin)
- Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprosthetic Heart Valve ReplacementRecruitingPhase 4Asan Medical CenterNCT07431762Written as Vitamin K antagonist(warfarin)
- Anticoagulation Therapy in Non-device-related Intra-cardiac ThrombusActive, not recruitingPhase 3Centre Hospitalier Universitaire de NīmesNCT05825573Written as Vitamin K antagonist
- Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CADCompletedPhase 3Stefan EngelterNCT02046460Written as Vitamin K antagonist
- Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)CompletedPhase 2BayerNCT00839163Written as Enoxaparin/Vitamin K-Antagonist
- Treatment of Post-STEMI Left Ventricular Thrombus With Optimized AnticoagulantStatus unknownPhase 3RenJi HospitalNCT03764241Written as Vitamin K Antagonist
- A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring AnticoagulationCompletedPhase 2Bristol-Myers SquibbNCT02981472Written as Vitamin K Antagonist (VKA)
- Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCompletedPhase 3Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyNCT02866175Written as Vitamin K antagonist
- Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical OutcomesTerminatedPhase 3BayerNCT02556203Written as Vitamin K antagonist (VKA)
- Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist TherapyCompletedPhase 4Atrial Fibrillation NetworkNCT02227550Written as Vitamin K antagonist
- Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for CardioversionCompletedPhase 3BayerNCT01674647Written as Vitamin K antagonist (VKA)
- Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein ThrombosisCompletedPhase 2BayerNCT00395772Written as (LMW) Heparin + Vitamin K Antagonist